Legal & General Group Plc boosted its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 5.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,923 shares of the company’s stock after acquiring an additional 3,042 shares during the quarter. Legal & General Group Plc’s holdings in Ionis Pharmaceuticals were worth $3,193,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently modified their holdings of IONS. TRUE Private Wealth Advisors acquired a new position in Ionis Pharmaceuticals in the third quarter valued at $133,000. Parallel Advisors LLC boosted its holdings in Ionis Pharmaceuticals by 195.5% in the third quarter. Parallel Advisors LLC now owns 3,023 shares of the company’s stock valued at $156,000 after acquiring an additional 2,000 shares during the last quarter. IFG Advisory LLC acquired a new position in Ionis Pharmaceuticals in the third quarter valued at $225,000. CIBC Asset Management Inc acquired a new position in Ionis Pharmaceuticals in the third quarter valued at $232,000. Finally, Private Advisor Group LLC acquired a new position in Ionis Pharmaceuticals in the third quarter valued at $238,000. Hedge funds and other institutional investors own 85.16% of the company’s stock.
NASDAQ:IONS opened at $58.05 on Thursday. The company has a current ratio of 7.99, a quick ratio of 7.96 and a debt-to-equity ratio of 0.74. Ionis Pharmaceuticals Inc has a one year low of $39.07 and a one year high of $59.81.
In related news, COO Brett P. Monia sold 34,000 shares of the business’s stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $55.00, for a total value of $1,870,000.00. Following the transaction, the chief operating officer now owns 49,841 shares in the company, valued at $2,741,255. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Patrick R. O’neil sold 19,600 shares of the business’s stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $59.25, for a total value of $1,161,300.00. Following the completion of the transaction, the senior vice president now owns 23,673 shares in the company, valued at approximately $1,402,625.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,290 shares of company stock worth $4,020,635. Insiders own 2.44% of the company’s stock.
A number of research analysts have commented on IONS shares. Leerink Swann started coverage on Ionis Pharmaceuticals in a research note on Tuesday, November 27th. They set a “market perform” rating and a $50.00 price objective on the stock. Morgan Stanley set a $46.00 price objective on Ionis Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 7th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research note on Wednesday, January 2nd. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Thursday, December 6th. Finally, Piper Jaffray Companies set a $50.00 price objective on Ionis Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, November 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $54.25.
WARNING: This report was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/4132838/ionis-pharmaceuticals-inc-ions-shares-bought-by-legal-general-group-plc.html.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Featured Article: Book Value Per Share – BVPS
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.